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Department of Cellular Biology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Košice, Slovakia
Hypericin (4,5,7,4′,5′,7′-hexahydroxy-2,2′-dimethylnaphtodianthrone) is a naturally
occurring chromophore found in some species of the genus Hypericum, especially
Hypericum perforatum L. (St. John’s wort), and in some basidiomycetes (Dermocybe
spp.) or endophytic fungi (Thielavia subthermophila). In recent decades, hypericin
has been intensively studied for its broad pharmacological spectrum. Among its
antidepressant and light-dependent antiviral actions, hypericin is a powerful natural
photosensitizer that is applicable in the photodynamic therapy (PDT) of various
oncological diseases. As the accumulation of hypericin is significantly higher in
neoplastic tissue than in normal tissue, it can be used in photodynamic diagnosis
(PDD) as an effective fluorescence marker for tumor detection and visualization. In
addition, light-activated hypericin acts as a strong pro-oxidant agent with antineoplastic
and antiangiogenic properties, since it effectively induces the apoptosis, necrosis or
autophagy of cancer cells. Moreover, a strong affinity of hypericin for necrotic tissue
was discovered. Thus, hypericin and its radiolabeled derivatives have been recently
investigated as potential biomarkers for the non-invasive targeting of tissue necrosis in
numerous disorders, including solid tumors. On the other hand, several light-independent
actions of hypericin have also been described, even though its effects in the dark have not
been studied as intensively as those of photoactivated hypericin. Various experimental
studies have revealed no cytotoxicity of hypericin in the dark; however, it can serve
as a potential antimetastatic and antiangiogenic agent. On the contrary, hypericin can
induce the expression of some ABC transporters, which are often associated with the
multidrug resistance (MDR) of cancer cells. Moreover, the hypericin-mediated attenuation
of the cytotoxicity of some chemotherapeutics was revealed. Therefore, hypericin
might represent another St. John’s wort metabolite that is potentially responsible for
negative herb–drug interactions. The main aim of this review is to summarize the
benefits of photoactivated and non-activated hypericin, mainly in preclinical and clinical
applications, and to uncover the “dark side” of this secondary metabolite, focusing on
MDR mechanisms.
Keywords: hypericin, St. John’s wort, anticancer activities, photodynamic therapy, photodynamic diagnosis, drug
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INTRODUCTION
Hypericin (4,5,7,4′,5′,7′-hexahydroxy-2,2′-dimethylnaphtodiant
hrone) is a naturally occurring compound synthesized by some
species of the genusHypericum. Hypericin was first isolated from
Hypericum perforatum L. (Brockmann et al., 1939), commonly
known as St. John’s wort, which is one of the best characterized
and most important representatives of this genus, because of
its broad pharmacological activity (antidepressant, antimicrobial,
anticancer, anti-inflammatory, wound healing, etc.) (reviewed
in Kasper et al., 2010; Wölfle et al., 2014). Hypericin and its
derivatives are accumulated in special morphological structures,
so called dark nodules, occurring in the aerial parts of
hypericin-producing Hypericum species. The newest data on
interspecific variation in localization of hypericins and spatial
chemo-profiling of hypericin in some Hypericum species were
published recently (Kusari et al., 2015; Kucharikova et al.,
2016).
In addition to St. John’s wort, this secondary metabolite
was found in several other Hypericum species (Kitanov, 2001;
Ayan et al., 2004) and in some basidiomycetes (Dermocybe spp.)
(Dewick, 2002; Garnica et al., 2003) or endophytic fungi growing
in Hypericum perforatum (Thielavia subthermophila) (Kusari
et al., 2008, 2009). As hypericin is a bioactive compound that
is applicable in several medicinal approaches, its content has
been evaluated in in vitro grown Hypericum perforatum and in
its transgenic clones (Cˇellárová et al., 1997; Košuth et al., 2003;
Koperdáková et al., 2009), or in Hypericum cultures exposed
to various biotechnological applications that focused on their
preservation or stimulation of secondary metabolite production
(Urbanová et al., 2006; Brunˇáková et al., 2015; reviewed in:
Cˇellárová, 2011).
Hypericin is well-known as a potent natural photosensitizing
agent with great potential in anticancer photodynamic therapy
(PDT) and photodynamic diagnosis (PDD). Besides its
antineoplastic action, light-dependent in vitro fungicidal
(Rezusta et al., 2012; Paz-Cristobal et al., 2014) and bactericidal
effects (Kashef et al., 2013; García et al., 2015) have also been
reported. In addition, light-activated hypericin is considered
Abbreviations: 1O2, singlet oxygen; 64Cu-bis-DOTA-hypericin, 64Cu-Labeled bis-
1,4,7,10-tetraazacyclododecane-N,N′ ,N,N′-tetraacetic acid conjugated hypericin;
ABC, ATP-binding cassette; AK, actinic keratosis; BCC, basal cell carcinoma;
BCRP, breast cancer resistance protein; BD, Bowen’s disease; CA4P, combretastatin
A4 phosphate; Cdk4, cyclin-dependent kinase 4; CIS, carcinoma in situ;
CLE, confocal laser endomicroscopy; CYP3A4, cytochrome P450 3A4; DAMPs,
damage-associated molecular patterns; DLI, drug–light interval; EGFR, epidermal
growth factor receptor; FE, fluorescence endoscopy; Hsp90, heat shock protein
90; HY-PDD, hypericin-mediated photodynamic diagnosis; HY-PDT, hypericin-
mediated photodynamic therapy; ICD, immunogenic cell death; INF-α, interferon-
α; LIF, laser-induced fluorescence; MDR, multidrug resistance; MF, mycosis
fungoides; MRP1, multidrug resistance-associated protein 1; NACA, necrosis-avid
contrast agent; O›−2 , superoxide anion; p53, phosphoprotein p53, tumor suppressor
p53, tumor protein p53; PDD, photodynamic diagnosis; PDT, photodynamic
therapy; P-gp, P-glycoprotein; Plk, Polo-like kinase; PVP, polyvinylpyrrolidone;
Raf-1, serine/threonine kinase, Raf-1 proto-oncogene; ROS, reactive oxygen
species; SCC, squamous cell carcinoma; Ser, serine; SN-38, 7-Ethyl-10-hydroxy-
camptothecin; TCC, transitional cell carcinoma; Thr, threonine; TNF-α, tumor
necrosis growth factor-α; TNT, tumor necrosis therapy; VEGF, vascular endothelial
growth factor; WLE, white-light endoscopy.
to be an effective antiviral agent (Hudson et al., 1993; Prince
et al., 2000). However, some clinical studies have revealed that
high doses of hypericin can induce phototoxic skin reactions
without showing any detectable antiviral or antiretroviral activity
in patients with viral infections (Gulick et al., 1999; Jacobson
et al., 2001). The controversy concerning the virucidal effect of
hypericin was summarized in detail by Kubin et al. (2005).
However, the potential use of this secondary metabolite in
medicine might be broader than currently thought. Although
hypericin has been extensively studied mainly because of its
photodynamic and photocytotoxic properties, it also possesses
various positive or negative biological activities without being
activated by light.
LIGHT-ACTIVATED HYPERICIN
Hypericin possesses several properties that make it a powerful
fluorescent photosensitizer that is suitable for PDT and PDD—
attractive applications for the treatment and detection of tumors.
It possesses minimal or no toxicity in the dark (Thomas
and Pardini, 1992; Vandenbogaerde et al., 1997; Miadokova
et al., 2010; Jendželovská et al., 2014; Feruszová et al., 2016),
accumulates preferentially in neoplastic tissues (Kamuhabwa
et al., 2002; Noell et al., 2011) and generates reactive oxygen
species (ROS) in the presence of light (at wavelengths around
600 nm) and oxygen (Diwu and Lown, 1993). Thus, hypericin
represents a potent natural alternative to chemically synthesized
photosensitizers.
Hypericin in Photodynamic Therapy
PDT represents a non-invasive therapeutic approach that is
beneficial in the treatment of various cancerous (reviewed in
Agostinis et al., 2011) and even non-cancerous lesions and
disorders (reviewed in Kim et al., 2015). In general, it is
based on the combined action of a photosensitizer, light and
molecular oxygen. PDT involves the administration of a non-
toxic photosensitizer that preferentially accumulates in the
target tissue, followed by its local illumination with harmless
visible light of an appropriate wavelength, to activate and excite
the photosensitizer. These photoreactions lead to the oxygen-
dependent generation of cytotoxic ROS, resulting in cell death
and tissue destruction. However, PDT is a multifactorial process
and the degree of cellular photodamage depends onmany factors,
including cell permeability, the subcellular localization of the
photosensitizer, the quantity of molecular oxygen, the light dose,
the types of generated ROS and the attributes of cancer cells.
The exact mechanisms of cellular hypericin uptake are still
unclear and require further investigation, but the results indicate
that hypericin might be transported into or through cells via
temperature-dependent diffusion (Thomas and Pardini, 1992;
Sattler et al., 1997), partitioning, pinocytosis or endocytosis
(Siboni et al., 2002). Concerning its subcellular redistribution, the
co-labeling of cancer cells with hypericin and fluorescent dyes
specific for cell organelles revealed that hypericin accumulates
in the membranes of the endoplasmic reticulum, the Golgi
apparatus, lysosomes and mitochondria (Agostinis et al., 2002;
Ali and Olivo, 2002; Galanou et al., 2008; Mikeš et al., 2011).
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However, the cellular uptake and subcellular localization of
hypericin might be affected by its lipophilicity, incubation
concentrations and/or interaction with serum lipoproteins
(Crnolatac et al., 2005; Galanou et al., 2008; Kascakova et al.,
2008). In brief, upon light-activation, hypericin is efficient
primarily in the generation of singlet oxygen (1O2; type II
mechanism) and superoxide anion (O›−2 ; type I mechanism)
(Thomas et al., 1992; Diwu and Lown, 1993), which can
ultimately lead to necrosis (Du et al., 2003b; Mikeš et al.,
2007, 2009), apoptosis (Ali and Olivo, 2002; Mikeš et al., 2009),
autophagy-associated cell death (Buytaert et al., 2006; Rubio
et al., 2012) or even to immunogenic cell death (ICD) (Garg
et al., 2012a). As type II ICD inducer (Garg et al., 2015a),
HY-PDT represents a promising form of active immunotherapy
(Galluzzi et al., 2014) owing to spatiotemporally defined emission
of damage-associated molecular patterns (DAMPs) (Garg et al.,
2012b, 2015b, 2016; Zheng et al., 2016).
The photocytotoxicity of hypericin is strongly oxygen-
dependent, as no such effects are present in hypoxic conditions
(Thomas and Pardini, 1992; Delaey et al., 2000). Nevertheless,
the final response of hypericin-mediated PDT (HY-PDT) might
also be affected by the ability of cells to overcome oxidative
stress through the activity of various cytoprotective mechanisms,
including cellular redox systems (Mikeš et al., 2011; Mikešová
et al., 2013). Furthermore, the light-dependent inhibitory effect
of hypericin against various enzymes engaged in the regulation
of cell survival and proliferation (Ser/Thr kinases, tyrosine
kinases, etc.) has been reported (reviewed in Kubin et al., 2005).
These activities might also contribute to the cytotoxic and
antiproliferative effects of HY-PDT. The exact mechanisms of
action and the cellular aspects of HY-PDT have been outlined
and summarized in several reviews (Agostinis et al., 2002;
Theodossiou et al., 2009; Mikeš et al., 2013; Garg and Agostinis,
2014).
Preclinical and Clinical Assessment of HY-PDT
Efficacy and Suitable Conditions
Many in vitro studies have demonstrated the cytotoxicity of
photoactivated hypericin in various cancer cell types (Xie et al.,
2001; Head et al., 2006; Sacková et al., 2006; Mikeš et al.,
2007; Koval et al., 2010; Mikešová et al., 2013; Kleemann et al.,
2014). Moreover, recent in vivo, preclinical and clinical studies
have indicated that HY-PDT might be an effective and relevant
approach in the treatment of some skin tumors, carcinomas
and sarcomas. In general, the depth of tumor destruction after
PDT commonly ranges from a few mm to 1 cm, due to limited
photosensitizer and light penetration through the tissues. Thus,
PDT is effective mostly against superficial lesions and small
tumors.
Clinical studies to test HY-PDT efficacy
To our knowledge, three clinical trials of HY-PDT applied to
various skin tumors have been published to date (Table 1).
In the first study, Alecu et al. (1998) tested the intralesional
injection of hypericin with subsequent photoactivation with
visible light in the treatment of basal cell carcinoma (BCC)
(eleven patients) and squamous cell carcinoma (SCC) (eight
patients) and found that HY-PDT was effective in the treatment
of both skin disorders. A reduction in tumor size and the
generation of a new epithelium at the surface of lesions following
HY-PDT were observed. Moreover, as no necrosis or cell loss
was evident in the surrounding healthy tissues and no side
effects were observed, with the exception of mild erythema in
five cases (two patients with SCC, three patients with BCC),
HY-PDT-mediated tumor targeting was selective. The treatment
resulted in a complete clinical response in one SCC patient
and two BCC patients, but in the remaining patients, only a
partial clinical response was observed. Thus, the efficacy of HY-
PDT appeared to be dependent on the initial lesion size, the
total dose of hypericin, or the frequency and duration of the
therapy (Alecu et al., 1998). Several years later, the potential
use of HY-PDT in the treatment of non-melanoma skin cancers
was explored (Kacerovská et al., 2008). A complete clinical
response was observed in 50% of patients with actinic keratosis
(AK) 3 months after HY-PDT, and in 22% of patients with
superficial BCC and 40% of patients with Bowen’s disease (BD)
6 months after HY-PDT. However, in the case of AK, the
percentage reduced to 29% 6 months after HY-PDT and only
partial remission was observed in patients with nodular BCC.
On the other hand, complete histological remission was evident
in 80% of patients with BD (Kacerovská et al., 2008). Only the
partial response rate and suboptimal success of HY-PDT could
be caused by the limited penetration of the skin by hypericin
and by its low concentration in the final extraction product. In
the third clinical trial, Rook et al. (2010) tested HY-PDT as a
potentially well-tolerated and effective therapeutic modality for
the treatment of lymphocyte-mediated skin disorders: malignant
mycosis fungoides (MF; the most common type of cutaneous
T-cell lymphoma) and non-cancerous autoimmune psoriasis.
The results were promising for both diseases. In the case of
MF, HY-PDT led to an improvement in the treated lesions
(a size reduction by at least 50%) in the majority of patients,
whereas the placebo was ineffective. Moreover, hypericin was
well tolerated by the patients, with only mild to moderate
phototoxic skin reactions occurring after exposure to visible light.
No serious adverse effects or events were observed (Rook et al.,
2010). However, the authors themselves recommended a phase
III study with a greater number of patients. All these clinical
data indicate that topically applied hypericin, combined with
its photoactivation, might be a promising and safe alternative
for the treatment of some cancerous and non-cancerous skin
disorders. However, as the effectiveness of HY-PDT depends
on the hypericin concentration, its total dose, its rate of tissue
penetration, the frequency and duration of the therapy, or on the
grade of malignancy, more clinical trials are necessary to define
the optimal conditions for the whole procedure.
Preclinical in vivo studies to test HY-PDT effects and
conditions
Many further studies to test HY-PDT efficacy have been
performed using mouse or rat animal models (Table 2).
Several in vivo studies indicate that HY-PDT might be a
promising approach in the treatment of bladder carcinomas.
Kamuhabwa et al. (2002) reported selective hypericin uptake
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TABLE 1 | Clinical studies to test HY-PDT efficacy.
Disease/No. of
patients
Hypericin
administration
Hypericin dosage Light
dose/Fluence
rate
HY-PDT efficacy References
Squamous cell
carcinoma/8
Intralesional
injection
40–100µg 3–5 times per week
for 2–4 weeks;
86 J/cm2/24
mW/cm2
Reduction in tumor size, re-epithelization
at the borders of the lesion, complete
clinical remission in the case of one
patient;
Alecu et al., 1998
Basal cell
carcinoma/11
40–200µg 3–5 times per week
for 2–6 weeks
Reduction in tumor size, complete clinical
remission in the case of two patients, no
evident signs of tumor recurrence after 5
months
Actinic keratosis/8
Basal cell
carcinoma/21
On the lesion Weekly for 6 weeks on average 75 J/cm2 50% complete clinical response (AK) 28%
complete clinical response (superficial
BCC) 11% complete histological response
(superficial BCC) 67% partial clinical
response (nodular BCC)
Kacerovská et al.,
2008
Bowen’s disease/5 40% complete clinical response (BD) 80%
complete histological response (BD)
Mycosis fungoides
(T-cell lymphoma)/12
On the lesion 0.005–0.025mg/cm2
twice-weekly for 6 weeks
8–20 J/cm2 58.3% of responsive patients (reduction in
MF lesion size by 50% or more)
Rook et al., 2010
Psoriasis/11 54.6% of responsive patients
AK, actinic keratosis; BCC, basal cell carcinoma; BD, Bowen’s disease; MF, mycosis fungoides.
in bladder tumors and subsequently, even HY-PDT-mediated
tumor damage was observed without the destruction of normal
tissue (Kamuhabwa et al., 2003). In both studies, female Fisher
rats with an orthotopic superficial transitional cell carcinoma
(TCC) were used as an experimental model and hypericin
was administered directly into the bladder via the catheter.
The instilled hypericin accumulated selectively in the bladder
urothelial tumors and the normal urothelium (in a ratio of 12:1),
but no hypericin was detected in normal bladder submucosa and
muscle layers, which is an important factor to avoid underlying
tissue damage. In addition, no hypericin was detected in plasma;
thus, systemic side-effects should not appear (Kamuhabwa et al.,
2002).
Furthermore, photoactivated hypericin resulted in selective
urothelial tumor damage, with tumor cells shrinking and
detaching from the bladder wall, indicating that HY-PDT might
be beneficial in the treatment of superficial carcinomas and
premalignant changes in the bladder. The HY-PDT that was
performed under suitable light conditions had no significant
effects on the other bladder layers; nevertheless, 2–5% of
tumor cells survived and were responsible for tumor regrowth
(Kamuhabwa et al., 2003). However, following the results of
in vitro study based on TCC-derived spheroids, the same
authors suggested that hyperoxygenation could overcome this
problem and might enhance the efficacy of HY-PDT (Huygens
et al., 2005). In addition to the orthotopic tumor model,
Liu et al. (2000) also used a xenograft model in their
experiments. Human MiaPaCa-2 pancreatic adenocarcinoma
cells were injected subcutaneously and orthotopically into the
pancreatic bed of nude, athymic mice. To allow hypericin
photoactivation in orthotopic pancreatic tumor nodules, mice
underwent a laparotomy that was necessary for the positioning of
the optical fiber. A significant decrease in growth of subcutaneous
shoulder tumors (91.2% ± 2.3%) and even pancreatic tumor
nodules (42.2% ± 8.1%) was observed 4 weeks after HY-PDT,
indicating that intratumor hypericin and laser therapy might also
be beneficial in the treatment of unresectable pancreatic cancer
(Liu et al., 2000).
However, instead of more clinically relevant orthotopic tumor
models, more in vivo studies have been performed to test the
efficacy, conditions or responses of HY-PDT after the treatment,
only in the murine or rat xenograft or allograft models of
subcutaneous carcinomas or sarcomas. Various positive effects of
HY-PDT involving the inhibition of tumor growth, a prolonged
survival time of the treated animals, tumor necrosis, apoptosis
or damage to the tumor vasculature were observed in mice
bearing human epidermoid carcinoma (Vandenbogaerde et al.,
1996), human prostate adenocarcinoma cells (Xie et al., 2001),
human nasopharyngeal carcinoma cells (Du et al., 2003a,b;
Thong et al., 2006), human squamous carcinoma cells (Head
et al., 2006), human bladder carcinoma cells (Bhuvaneswari
et al., 2008), human rhabdomyosarcoma cells (Urla et al., 2015),
murine lymphoma cells (Chen and de Witte, 2000), murine
colon adenocarcinoma cells (Blank et al., 2002; Sanovic et al.,
2011), murine fibrosarcoma cells (Cˇavarga et al., 2001, 2005;
Chen et al., 2001, 2002a,b; Bobrov et al., 2007) or murine Ehrlich
ascites carcinoma cells (Lukšiene˙ and De Witte, 2002) and in
rats bearing rat bladder transitional bladder carcinoma (Zupkó
et al., 2001) or rat pituitary adenoma cells (Cole et al., 2008)
(Table 2). In addition, Blank et al. (2002) demonstrated the
dependence of HY-PDT efficacy on the irradiation conditions
(light dose and wavelength). Tumor necrosis was much more
pronounced at 590 nm than at 550 nm and even increased
when the light dose was raised from 60 to 120 J/cm2; however,
the maximum depth of tumor necrosis was 9.9 ± 0.8mm
at 590 nm (Blank et al., 2002). Considering the relationship
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TABLE 2 | Preclinical in vivo studies to test HY-PDT effects and conditions.
Experimental model/Type of
tumor (cell line)
Hypericin
administration
Hypericin dose Light dose/Fluence
rate
HY-PDT effects References
Athymic nude mice/Epidermoid
carcinoma (A431)
Intraperitoneal
injection
2.5mg/kg,
5mg/kg
180 J/cm2 Tumor growth
inhibition, reduced
tumor mass
Vandenbogaerde et al.,
1996
Athymic nude mice/Pancreatic
carcinoma (MiaPaCa-2)
Intratumoral Injection 10µg/mouse 2 doses of 200 J Suppressed growth of
subcutaneous and
orthotopic tumors
Liu et al., 2000
DBA/2 mice/Lymphoma (P388) Intraperitoneal
injection
2, 5 or 20mg/kg 120 J/cm2/100mW/cm2 Reduced tumor mass
and tumor size,
prolonged survival time
Chen and de Witte,
2000
Nude mice/Prostate carcinoma
(LNCaP)
Oral 5mg/kg 30mW Tumor growth inhibition Xie et al., 2001
C3H/Km mice/Fibrosarcoma
(RIF-1)
Intravenous injection 5mg/kg 120 J/cm2/100mW/cm2 Tumor vasculature
damage after 0.5 h DLI
PDT resulting in
complete tumor cure,
apoptosis as a main
form of cell death
Chen et al., 2001,
2002a,b
Fischer CDF (F344)/CrlBR
rats/Bladder carcinoma (AY-27)
Intravenous injection 1 or 5 mg/kg 120
J/cm2/100mW/cm2
Reduced tumor size,
no measurable tumor
mass 9–10 days after
0.5 h DLI PDT
Zupkó et al., 2001
C3H/DiSn mice/Fibrosarcoma
(G5:1:13)
Intratumoral or
intraperitoneal
injection
5 mg/kg 180 J/cm2/150
mW/cm2
Reduced tumor
volume, prolonged
survival time, complete
remission in smaller
lesions (3mm or less in
size)
Cˇavarga et al., 2001
Intraperitoneal
injection
1 × 5mg/kg, 2 ×
2.5mg/kg
168 J/cm2/70mW/cm2 Higher efficiency of
fractionated dose
Vascular damage,
formation of necrotic
areas
Cˇavarga et al., 2005;
Bobrov et al., 2007
Balb/c mice/Colon carcinoma
(C26)
Intraperitoneal
injection
5mg/kg 60, 90 or
120 J/cm2/100mW/cm2
Vascular damage,
tumor necrosis (the
depth of tumor
necrosis increased with
increased light dose)
Blank et al., 2002
Balb/c mice/Ehrlich ascites
carcinoma
Intraperitoneal
injection
40mg/kg 50mW/cm2 Prolonged survival time
(75% of mice), no
tumor recurrence (25%
of survived mice)
Lukšiene˙ and De Witte,
2002
Fischer rats/Bladder carcinoma
(AY-27)
Instillation into the
bladder
30µM 6–48 J/cm2/25–50
mW/cm2
Selective urothelial
tumor damage without
destructive effects on
detrusor musculature
Kamuhabwa et al., 2003
Balb/c nude
mice/Nasopharyngeal carcinoma
(HK-1)
Intravenous injection 2 mg/kg 120 J/cm2/226
mW/cm2
Inhibited tumor growth,
tumor shrinkage,
necrosis as a main
form of cell death
Du et al., 2003a,b
2 or 5mg/kg 30 J/cm2/25mW/cm2 Increased apoptosis
and lower serum levels
of VEGF after 6 h DLI
PDT
Thong et al., 2006
Athymic nude mice/Squamous
carcinoma (SNU1)
Intratumoral injection 10µg per mg
tumor
0–60 J/cm2 Regression of smaller
tumors (under
400mm3 )
Head et al., 2006
(Continued)
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TABLE 2 | Continued
Experimental model/Type of
tumor (cell line)
Hypericin
administration
Hypericin dose Light dose/Fluence
rate
HY-PDT effects References
Balb/c nude mice/Bladder
carcinoma (MGH)
Intravenous injection 5mg/kg 120 J/cm2/100mW/cm2 Vascular damage after
0.5 h DLI PDT resulting
in reduced tumor
volume, increased
expression of some
angiogenic proteins
after 6 h DLI PDT
Bhuvaneswari et al.,
2008
Wistar-Furth rats/Pituitary
adenoma (GH4C1)
Intraperitoneal
injection
4 × 1mg/kg 105–130 J/m2 Inhibited growth of
smaller tumors (under
1 cm3 ), formation of
apoptotic clusters
Cole et al., 2008
NMRI – HR-HR hairless
mice/UV-induced small skin
tumors
Topical application 0.1% in gelcream 40 J/cm2/20mW/cm2 Full lesional necrosis
resulting in total lesional
clearance (44%),
replacement of atypical
AK cells by normal
keratinocytes
Boiy et al., 2010
Balb/c mice/Colon carcinoma
(CT26)
Intravenous injection 2.5 or 10mg/kg 14 or 60 J/cm2/27 or
50mW/cm2
Vascular damage after
“low power PDT”
resulting in complete
tumor regression,
prevention of new
tumor growth after the
re-challenge of cured
mice with CT26 cells
Sanovic et al., 2011
NOD/LtSz-scid IL2Rγnull
mice/Rhabdomyosarcoma
(Rh30)
Intravenous injection 100µg/mouse —- Induction of apoptosis
in tumor cells
Urla et al., 2015
Balb/c mice/Colon carcinoma
(CT26)
Subcutaneous
injection of HY-PDT
treated cells
150 nM 2.70 J/cm2 Tumor-rejecting
anticancer vaccination
effect after the
re-challenge of cured
mice with CT26 cells
Garg et al., 2012a,
2015b, 2016
Fischer 344 rats/Rat bladder
carcinoma (AY27)
Subcutaneous
injection of HY-PDT
treated cells
150 nM 2.70 J/cm2 Absence of
tumor-rejecting
anticancer vaccination
effect after the
re-challenge of cured
rats with AY27 cells
Garg et al., 2015b
C57BL/6 mice/Lewis lung
carcinoma (LLC), Dendritic cells
(DC) co-cultured with PDT-LLCs
Subcutaneous
injection of HY-PDT
treated cells
0.25µM 1.85 J/cm2 Tumor-rejecting
anticancer vaccination
effect after the
re-challenge of cured
mice with LLC-Luc
cells
Zheng et al., 2016
AK, actinic keratosis; DLI, drug-light interval; VEGF, vascular endothelial growth factor; –, the parameter was not provided by the authors.
between HY-PDT efficacy and tumor volume, similar results
were obtained in other studies. Head et al. (2006) and Cole
et al. (2008) observed a regression or reduction in tumor
size only in tumors smaller than 0.4 or 1 cm3, respectively,
whereas larger tumors showed only a partial response followed
by their regrowth (Head et al., 2006), or did not respond to
the treatment (Cole et al., 2008). Thus, light penetration into
the tissue appeared to be a limiting factor. However, Cole
et al. (2008) also concluded that HY-PDT can be effective
in the elimination of small solid tumor residues. Cˇavarga
et al. (2001) also determined complete remission only in
smaller tumors (3mm or less in height), but the main aim of
their study was to compare the impact of intraperitoneal and
intratumoral hypericin injection on the effectiveness of HY-PDT.
Both schedules of hypericin administration significantly reduced
tumor volume and increased the survival rate of animals.
However, considering the complete response, a higher HY-
PDT efficacy was observed for hypericin that was administered
intraperitoneally (44.4%) compared to intratumorally (33.3%)
(Cˇavarga et al., 2001). Moreover, it was later demonstrated that
a better therapeutic response was obtained after fractionated
hypericin administration (two 2.5mg/kg doses; 6 and 1 h before
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irradiation) than after a single hypericin dose (5mg/kg; 1 or 6 h
before irradiation) (Cˇavarga et al., 2005).
Furthermore, Chen et al. (2001) reported the correlation
between hypericin biodistribution, HY-PDT efficacy and various
administration–irradiation time intervals (drug–light intervals—
DLIs). It was found that shortly (0.5 h) after the intravenous
administration of hypericin (5mg/kg), the photosensitizer was
located preferentially within tumor blood vessels. At 6 h
after injection, maximum intratumoral hypericin content was
evident and only poor fluorescence was detected in the tumor
vasculature. Despite high tumor hypericin levels, no tumor
cure was observed after longer DLI HY-PDT (6 h) treatment.
However, the efficacy of PDT was maximal (100% tumor
cure) when irradiation was performed at 0.5 h after hypericin
administration (short DLI), indicating strong HY-PDT-induced
damage to the tumor vasculature (Chen et al., 2001). Similar
results were obtained by Zupkó et al. (2001). In TCC tumors,
the outcome of HY-PDT was highly dependent on DLI (0.5,
6, or 24 h). The strongest effect, which resulted in no tumor
regrowth in some rats, was evident after 0.5 h DLI PDT. At
the same time, the highest hypericin concentration was detected
in the plasma, indicating that PDT-mediated tumor vascular
damage was responsible for its antineoplastic action (Zupkó et al.,
2001). The antivascular and strong antitumoral effects of short
DLI HY-PDT were also subsequently confirmed in the murine
fibrosarcoma model (Chen et al., 2002a,b). Damage to tumor
vessels was also detected following long DLI HY-PDT treatments,
but many viable tumor cells were present, especially at the tumor
periphery, indicating that this PDTmodality only induced partial
vascular collapse (Chen et al., 2002a). In agreement with these
results, Bobrov et al. (2007) also observed primary vascular
damage after HY-PDT with either a single dose (5 mg/kg; 1 or
6 h before irradiation) or fractionated hypericin administration
(two 2.5 mg/kg doses; 6 and 1 h before irradiation), which
subsequently progressed to tumor tissue necrosis. The preference
of HY-PDT-mediated vasculature or cellular damage appears
to be dependent on the distribution and accumulation of the
photosensitizer; thus, greater vascular destruction is expected
after short DLI PDT and more direct killing of tumor cells is
expected after long DLI PDT. However, because the damage
to tumor vessels can have devastating consequences for whole
tumor mass, the targeting of the tumor vasculature via short
DLI PDT might be more effective in the treatment of solid
tumors than a long DLI PDT. Moreover, apoptosis was the main
form of cell death responsible for tumor eradication following
short DLI HY-PDT (Chen et al., 2002b). In contrast, Thong
et al. (2006) observed significantly more apoptosis after long
DLI PDT (6 h) compared to short DLI PDT (1 h). However,
different irradiation conditions and tumor models were used
in both studies: whereas Chen et al. (2002b) photoactivated
hypericin with a light dose of 120 J/cm2 delivered at a fluence
rate of 100mW/cm2, a lower fluence rate HY-PDT (light dose
of 30 J/cm2, fluence rate of 25mW/cm2) was applied by Thong
et al. (2006). The results indicate that long DLI PDT might also
be effective in the induction of programmed cell death, but only
under low fluence rate conditions. Moreover, lower serum levels
of vascular endothelial growth factor (VEGF) were detected after
HY-PDT using a long DLI and a low fluence rate, which can
reduce the risk of new tumor vasculature formation (Thong et al.,
2006).
As PDT-mediated tissue damage can lead to various cellular
and molecular responses, Bhuvaneswari et al. (2008) examined
the potential anti-angiogenic vs. angiogenic properties of short
(0.5 h) and long (6 h) DLI HY-PDT. Both HY-PDT scenarios led
to a reduction in tumor volume, but the effect was much more
pronounced for a short DLI. These findings agree with the above-
mentioned results (Chen et al., 2001, 2002a,b) and suggest the
destruction of the tumor vasculature after short DLI HY-PDT.
However, in addition to its antitumor activities, cellular-targeted
long DLI HY-PDT induced the expression of some angiogenic
proteins in tumor tissue, including VEGF, tumor necrosis growth
factor-α (TNF-α) and interferon-α (INF-α), which potentially
lead to the formation of new vessels (Bhuvaneswari et al., 2008).
In subsequent studies, the efficacy of HY-PDT was enhanced
using monoclonal antibodies against VEGF and the epidermal
growth factor receptor (EGFR) (Bhuvaneswari et al., 2010, 2011).
For short DLI HY-PDT, similar results were obtained by Sanovic
et al. (2011) in mice bearing CT26 colon carcinoma cells.
Complete tumor regression was observed after “low-power HY-
PDT” (a hypericin dose of 2.5mg/kg, a short DLI of 0.5 h, a
light dose of 14 J/cm2 and a fluence rate of 27mW/cm2), as no
visible or palpable tumors were detected for at least 60 days
after the treatment. In contrast, all mice exposed to “high-power
HY-PDT” (a hypericin dose of 10mg/kg, a short DLI of 1 h, a
light dose of 60 J/cm2 and a fluence rate of 50mW/cm2) died 2
days after the treatment as a consequence of internal bleeding.
Thus, both HY-PDT modalities with short DLIs appeared
to preferentially target the vessels, but a higher hypericin
concentration and light dose produced amuch stronger response.
These results suggest that “low-power HY-PDT” is strong enough
to completely eliminate tumors by damaging their vasculature.
Moreover, the re-challenge of cured mice with tumorigenic CT26
cells did not result in new tumor growth, indicating the HY-
PDT-mediated induction of the antitumor immune response
(Sanovic et al., 2011). HY-PDT-mediated induction of anticancer
immunity was also observed in the studies utilizing different
in vivo experimental models. Immunization of BALB/c mice
with “dying or dead” colon carcinoma CT26 cells prevented
the tumor growth at the rechallenge site treated with live CT26
tumor cells. Approximately 70–85% of the mice immunized with
HY-PDT treated CT26 cells efficiently rejected the formation
of CT26-derived tumors at challenge site (Garg et al., 2012a,
2015b, 2016). Activation of adaptive immune system was also
detected in immunocompetent C57BL/6 mice immunized with
HY-PDT treated Lewis lung carcinoma (LLC) cells and LLC cells
co-cultured with dendritic cells (Zheng et al., 2016). The results
of these three independent experimental groups suggest great
potential of HY-PDT in development of anticancer vaccines.
Similar results as in the case of partial remission in patients
with nodular BCC (Kacerovská et al., 2008) were obtained in
an in vivo study using hairless mice with UV-induced non-
melanoma skin tumors (AK, SCC) as an experimental model
(Boiy et al., 2010). Photoactivated hypericin induced a total and
partial response in 44 and 22% of lesions (diameter of 1–2mm),
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respectively, with evident lesional necrosis and the replacement
of atypical AK cells for normal keratinocytes. However, 33% of
lesions were non-responsive to HY-PDT. Tumor penetration and
the selectivity of topically applied hypericin was also limited by
mouse skin, as the accumulation of hypericin was highest in
the outermost epidermal layer and lower hypericin levels were
detected in the rest of the epidermis and the dermis (Boiy et al.,
2010).
Some preclinical and clinical results gave relatively
disappointing results and in some cases, the efficacy of HY-
PDT was not as high as expected. The above-mentioned studies
contributed to a better understanding of HY-PDT-induced
responses and highlighted the importance of optimizing the
conditions, such as suitable hypericin administration, light
dose, fluence rate, or time intervals and implicated HY-PDT
as a promising anticancer therapeutic approach; however,
more clinically relevant studies and trials are required for the
implementation of HY-PDT into clinical practice.
Hypericin in Photodynamic Diagnosis
In addition to their therapeutic abilities, most photosensitizers
are also potent diagnostic agents. The main principle and
relevance of PDD is to enhance the contrast between neoplastic
and surrounding healthy tissue, which should contribute to the
surgical clearance of the whole tumor mass or its small residues.
Due to the fluorescent properties of hypericin and its specificity
for neoplastic tissue, hypericin-mediated PDD (HY-PDD) is
being tested for various clinical uses, including optical tumor
imaging, and the targeting, monitoring or detection of tumor
stages and grades. To date, fluorescence diagnosis using hypericin
has been clinically tested in bladder, head and neck cancers or
gliomas (Table 3).
HY-PDD in the Detection and Identification of Bladder
Cancer
In most published clinical studies, HY-PDD was applied to
bladder tumors. As already mentioned in the HY-PDT section,
Kamuhabwa et al. (2002) (Table 4) revealed selective hypericin
uptake in rat bladder tumors using in situ laser-induced
fluorescence (LIF) and fluorescence microscopy. The results
suggest that hypericin is very beneficial in visualization and
distinguishing the tumor mass from normal tissue using various
fluorescent techniques. Thus, hypericin could be used not only in
PDT, but also in the PDD of superficial bladder tumors.
At about the same time, the first clinical studies were
performed by D’Hallewin et al. (2000, 2002), who examined
the fluorescence-based detection of flat bladder carcinomas in
situ (CIS) and in papillary non-invasive bladder tumors after
the intravesical instillation of hypericin (at least 2 h). The
fluorescence emission was induced using fluorescence endoscopy
(FE) under blue-light illumination. Hypericin accumulated
selectively in tumor cells and papillary and flat lesions showed
red fluorescence, whereas no fluorescence was evident in the
normal bladder tissue. Subsequently, biopsies were taken from
fluorescent regions for microscopic analyses. The results of both
clinical studies suggested that HY-PDD has a high sensitivity
and specificity for the detection of bladder cancer (D’Hallewin
et al., 2000, 2002). Moreover, the results obtained by confocal
microscopy, white-light endoscopy (WLE) and histopathology
revealed that the intensity of hypericin fluorescence increased
with the stage and grade of bladder cancer (normal bladder tissue
< inflammation in the bladder < grade 1 TCC < grade 2 TCC
< CIS < grade 3 TCC) (Olivo et al., 2003b). Therefore, HY-PDD
could be used as a diagnostic aid to the histopathology of bladder
tumors.
Nowadays, bladder lesions are conventionally diagnosed
under WLE followed by biopsies that are necessary for the
histological examination of suspicious tissues. However, in
previous studies, some lesions were barely visible or were absent
in white light (D’Hallewin et al., 2000, 2002), thus, WLE appears
not to be sensitive enough to reveal all CIS lesions and leads
to a high risk of missing the tumor. Therefore, another clinical
study compared the WLE and HY-PDD methods (Sim et al.,
2005). Hypericin was instilled into the bladder (for 2 h) and
immediately after WLE, FE (violet light) was used to induce
fluorescence emission in the same bladder regions. Despite the
comparable specificity of both approaches (91% for HY-PDD,
98% for WLE), HY-PDD was more sensitive (82%) than WLE
(62%) (Sim et al., 2005), suggesting that hypericin might be
very potent in the labeling and early detection of flat superficial
bladder tumors. Similar results were obtained by Kubin et al.
(2008) using polyvinylpyrrolidone (PVP) bound to hypericin as
a new water-soluble formula for the improvement of hypericin-
mediated bladder cancer detection and diagnosis. Hypericin-
PVP was intravesically instilled 1–2 h prior to FE. The overall
sensitivity of PDD with PVP-hypericin (95%) was significantly
higher than WLE (85%). The maximum contrast in sensitivity
was evident in the case of CIS (100% for PDD vs. 33% for WLE)
and dysplasia (85% for PDD vs. 31% for WLE) (Kubin et al.,
2008).
As the PVP–hypericin complex represents a potent water-
soluble PDD agent without the necessity of binding to serum
proteins, its biodistribution (Vandepitte et al., 2010) and optimal
dosage and instillation time were evaluated (Straub et al., 2015)
in tumor-bearing rats and in patients with bladder cancer,
respectively. Vandepitte et al. (2010) (Table 4) demonstrated
the uniform distribution of instilled PVP–hypericin in all cell
layers of the malignant urothelium, whereas its penetration
into the normal bladder epithelium was very limited. Straub
et al. (2015) tested various combinations of PVP–hypericin
dosage (75 and 225µg) and instillation time (15, 30, 60,
and 120min) to identify the optimal PDD conditions. Even
though the fluorescence of 225 µg PVP-hypericin instilled
for 120 and 60 min was very strong, the shorter instillation
time (30min) for 225µg PVP–hypericin was evaluated as
optimal. A lower photosensitizer dose (75µg) and 15 min
with a dose of 225µg were insufficient to detect the lesions
(Straub et al., 2015). The authors established the most suitable
dosage and instillation time of PDD with PVP–hypericin, but
they suggest a larger phase IIB study should be performed
to determine the sensitivity and specificity of these optimal
conditions.
All the above-mentioned results indicate that HY-PDD
is highly sensitive in the detection of early bladder cancer
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TABLE 3 | Clinical studies to test HY-PDD efficacy, sensitivity and specificity.
No. of patients Hypericin administration Hypericin dose Fluorescence excitation HY-PDD efficacy References
BLADDER CANCER
40 Instillation into the bladder 8µM (40ml) FE/blue light 93% sensitivity and 98.5%
specificity (for CIS)
D’Hallewin et al.,
2000
87 Instillation into the bladder 8µM (40ml) FE/blue light 94% sensitivity and 95%
specificity (for CIS)
D’Hallewin et al.,
2002
30 Instillation into the bladder 8µM (50ml) FE/blue light Fluorescence intensity
increased with the stage
and grade of cancer
(normal < inflammation <
grade 1 TCC < grade 2
TCC < CIS < grade 3
TCC)
Olivo et al., 2003b
41 Instillation into the bladder 8µM (40ml) FE/violet light Higher sensitivity (82%)
compared to conventional
WLE (62%)
Sim et al., 2005
57 Instillation into the bladder 0.25mg HY +
25mg PVP (50ml)
FE/blue light Higher overall sensitivity
(95%) compared to
conventional WLE (85%),
fewer overlooked
malignant lesions
compared to WLE,
sensitivity increased with
the grade of cancer
Kubin et al., 2008
40 Instillation into the bladder 75 or 225 µg
PVP-hypericin
(50ml)
FE/blue light very strong fluorescence
of 225µg PVP-hypericin
(120 and 60min), optimal
fluorescence of 225µg
PVP-hypericin instilled for
30min, insufficient
fluorescence of 75µg and
225µg PVP-hypericin
(15min)
Straub et al., 2015
8 Instillation into the bladder 8 µM (40ml) FM/380–425 nm Ex vivo urine fluorescence
cytology—fluorescence
detected in all eight tumor
cases
Pytel and
Schmeller, 2002
29 urine samples Ex vivo staining of sediment extracted
from voided urine
Concentration not
given (1ml)
CFM/488 nm Argon laser Higher fluorescence
intensity in tumor cells
than in cells from normal
urine and in high-grade
tumors than in low-grade
tumors
Olivo et al., 2003a
21 Ex vivo staining of sediment extracted
from voided urine
Concentration not
given (1ml)
CFM/488 nm Argon laser Higher fluorescence
intensity in tumor cells
than in cells from normal
urine
Fu et al., 2007
GLIOMA
5 Intravenous injection 0.1mg/kg NM/blue light Tumor fluorescence
clearly distinguishable
from normal brain tissue,
high specificity (100 and
90%) and sensitivity (91
and 94%)
Ritz et al., 2012
HEAD AND NECK CANCER
23 Oral rinsing 8µM (100ml) FE/blue light Distinguishing between
various types of oral
cancer (red-to-blue ratio),
90% and higher specificity
and sensitivity (red-to-blue
ratio)
Thong et al., 2009
(Continued)
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TABLE 3 | Continued
No. of patients Hypericin administration Hypericin dose Fluorescence excitation HY-PDD efficacy References
2 Oral rinsing 8 µM (100ml) CLE/488 nm Argon laser 3-D visualization of human
buccal mucosa at the
surface and approximately
15 µm below the surface
Thong et al., 2012
27 Ex vivo tissue staining 8µM pCLE/568 nm laser diode longer time interval for
sufficient ex vivo staining
(at least 30min), the
anomalies of keratinization
not stained
Abbaci et al., 2015
CIS, carcinoma in situ; CFM, confocal fluorescence microscopy; CLE, confocal laser endomicroscopy; FE, fluorescence endoscopy; FM, fluorescence microscopy; HY, hypericin; NM,
neurosurgical microscopy; pCLE, probe-based CLE; PVP, polyvinylpyrrolidone; TCC, transitional cell carcinoma; WLE, white-light endoscopy.
TABLE 4 | Preliminary data for clinical HY-PDD applications and in vivo studies concerning hypericin accumulation.
Experimental
model/Type of tumor
(cell line)
Hypericin
administration
Hypericin dose Fluorescence
excitation
Hypericin accumulation and
fluorescence
References
Fischer rats/Bladder
carcinoma (AY-27)
Instillation into the
bladder
8 or 30µM LIF/410 nm Krypton
laser FM/525/50 nm
Intense fluorescence in tumor
tissue and faint fluorescence in
normal bladder tissue (ratio 12:1),
no fluorescence in submucosa
and muscle layers
Kamuhabwa et al., 2002
30µM
PVP-hypericin
FM/510–560 nm Higher accumulation (3.5-fold
more) in malignant tissue than in
normal urothelium
Vandepitte et al., 2010
Wistar rats/Glioma (C6) Intravenous
injection
5 mg/kg FM/510–550 nm Higher accumulation in glioma
than in normal brain tissue and
infiltration zone
Noell et al., 2011
VMDk mice/Glioma
(SMA-560)
Intravenous
injection
2.5mg/kg FM/510–550 nm
FME/405 nm
Time-dependent accumulation in
glioma cells (maximal uptake—6h
after administration),
FME—fluorescence detection
also in intracerebral and
extracranial gliomas and in brain
vessels
Noell et al., 2013
NOD/LtSz-scid IL2Rγnull
mice/Rhabdomyosarcoma
(Rh30)
Intravenous
injection
100µg/mouse FL/blue light Tumor fluorescence clearly
distinguishable from normal
healthy tissue
Urla et al., 2015
CLE, confocal laser endomicroscopy; FL, fluorescence laparoscopy; FM, fluorescence microscopy; FME, fluorescence microendoscopy; LIF, laser-induced fluorescence technique.
and could be routinely used as a diagnostic approach.
Moreover, no photobleaching during FE and resection or
side effects were detected (D’Hallewin et al., 2002; Olivo
et al., 2003b; Sim et al., 2005; Kubin et al., 2008). Kamuhabwa
et al. (2005) also conclude that either photosensitization
or systemic side-effects should not be expected in patients
after intravesical hypericin administration, as the hypericin
concentration in plasma was below the detection limit
(<6 nM).
Another common method used for bladder cancer diagnosis
is ex vivo urine cytology, which microscopically analyzes the
exfoliated bladder cells from voided urine. This diagnostic
technique is non-invasive and less time-consuming than taking
biopsy specimens. However, its sensitivity to detect early-stage
or low-grade cancer is relatively low. Thus, several teams have
focused on a technique that combines HY-PDD and urine
cytology (Pytel and Schmeller, 2002; Olivo et al., 2003a; Fu
et al., 2007). In the first study conducted by Pytel and Schmeller
(2002), voided urine was analyzed in eight patients following
intravesically instilled hypericin (for at least 1 h). Even though
the number of patients was quite low, hypericin fluorescence was
detected in all cases of bladder cancer. On the contrary, Olivo
et al. (2003a) and Fu et al. (2007) performed HY-PDD-mediated
urine cytology without intravesical instillation of hypericin. In
both studies, sediments extracted from patient urine samples
were incubated with hypericin in the dark for 15min and were
subsequently analyzed using confocal fluorescence microscopy.
The overall fluorescence intensity of the urothelial cells was
significantly higher in urine from early-grade TCC than in
normal samples, which enabled the differentiation between
normal and early bladder cancer specimens (Olivo et al., 2003a).
This finding was later confirmed through a diagnostic algorithm
(Fu et al., 2007). Moreover, fluorescence was even higher in
high-grade tumors than in low-grade tumors (Olivo et al.,
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2003a). The results indicate that ex vivo fluorescence cytology
using hypericin might be a promising diagnostic method for
the detection and identification of early and low-grade bladder
cancer.
HY-PDD in the Detection of Gliomas
It is well-known that malignant gliomas are tumors with a
very poor prognosis and their complete resection significantly
improves and extends the survival of patients. Thus, in
these cases, the enhancement of the contrast between tumor
and surrounding healthy tissue would be very beneficial for
surgeons.
In the first in vivo study, Noell et al. (2011) (Table 4)
investigated the accumulation of hypericin in tumors arising
from intracerebrally implanted C6 glioma cells, in the zones
surrounding the tumors and in healthy brain tissue. Hypericin
was injected intravenously and its uptake was maximal 24 h
after injection. Considering tissue autofluorescence, the ratios of
fluorescence intensities were as follows: tumor:infiltration
zone:normal tissue = 19.8:2.5:1.0. Because hypericin
accumulation was significantly higher in the tumor than in
normal tissue, it could be effectively used as a fluorescence
marker for glioma detection (Noell et al., 2011). According to
these promising preliminary results, the hypericin-mediated
visualization of tumor tissue during its surgical resection
was examined in five patients with recurrent glioblastomas
(Ritz et al., 2012). Hypericin was injected intravenously 6 h
prior to the surgical procedure, which was performed using a
neurosurgical microscope under switchable white- and blue-light
modes. Malignant tumor tissue (red fluorescence) was clearly
distinguishable from the healthy brain tissue (blue color) in all
patients and the margins of the tumors showed weaker pink
fluorescence. Moreover, specimens were taken for histological
evaluation, which was carried out by two neuropathologists and
showed 100 and 90% specificity and 91 and 94% sensitivity.
The obtained results suggest that HY-PDD is well-tolerated and
represents a method that is sufficiently sensitive and specific for
the intraoperative visualization of malignant gliomas (Ritz et al.,
2012).
Furthermore, time-dependent hypericin uptake was
investigated and observed in a subcutaneous glioma mouse
model using microendoscopy, an approach that is not designed
for microsurgical tumor resection, but is very useful for
applications such as the visualization of different tissue
compartments, the identification of vessels or the detection
of optimal regions for biopsy. To verify the potential to
detect intracerebral gliomas using microendoscopy, tumor
cells were also implanted into the brain. After craniotomy,
hypericin fluorescence was detected in intracerebral and
extracranial gliomas and also in the vessels located in the cortical
surface of the contralateral hemisphere (Noell et al., 2013)
(Table 4).
HY-PDD in the Detection and Visualization of Other
Types of Malignancies
In addition to the above-mentioned studies, HY-PDD was also
examined in mice bearing rhabdomyosarcoma (Urla et al., 2015)
and in patients with various types of head and neck cancer
(Thong et al., 2009, 2012; Abbaci et al., 2015) (Tables 3, 4).
Similarly to bladder cancer, lesions in the oral cavity
are conventionally diagnosed using WLE and histopathology.
However, the results obtained by Thong et al. (2009) demonstrate
the great potential of hypericin for the diagnosis of various
oral cancer types (hyperplasia, cellular pleomorphic adenoma
of the palate, dysplasia, SCC). After oral rinsing with hypericin
solution (over 30 min), FE was performed and the captured
images were analyzed using several parameters. Firstly, the
selective uptake of hypericin in tumor tissue was confirmed.
Moreover, an increase in the red-to-blue fluorescence intensity
ratio was evaluated from normal tissue (0.3) to hyperplasia
(1.0) to SCC (2.0), which makes this parameter suitable for
distinguishing between these tissue types with high specificity
and sensitivity (over 90%) (Thong et al., 2009). Subsequently, the
endomicroscopy imaging technique was improved by the same
research team (Thong et al., 2012). Preliminary study already
suggested that confocal laser endomicroscopy (CLE) might be
a potent approach for the surface and subsurface imaging of
oral cavity tissues using various fluorescent dyes in both animal
and human models (Thong et al., 2007). Recently, a computing
systemwas interfaced to CLE, which enables the 3-D fluorescence
visualization of the oral cavity in real-time (Thong et al., 2012).
This system could be integrated into current techniques for oral
cancer diagnosis and might ultimately lead to better clinical
outcomes.
The fluorescent properties of hypericin and four
additional fluorescent dyes were also tested for their ability
to characterize normal and cancerous head and neck
tissue; however, the staining procedure was performed
ex vivo on fresh samples obtained from head and neck
surgeries (glossectomy, pharyngolaryngectomy, laryngectomy,
etc.). Hypericin accumulated in the cytoplasm of normal
and tumor cells, but was the only fluorescent dye that
did not stain the anomalies of keratinization. Thus, the
authors conclude that hypericin might not be a suitable
photosensitizer for use in such head and neck specimens
(Abbaci et al., 2015).
However, more promising in vivo results were obtained
for intra-operative HY-PDD of rhabdomyosarcoma. In
the preclinical study conducted by Urla et al. (2015),
mice were injected intraperitoneally with human alveolar
rhabdomyosarcoma cells and 3 weeks later, hypericin was
administered intravenously. After 24 h, conventional and
fluorescence laparoscopy were performed and the tumors were
surgically resected using hypericin-mediated red fluorescence
as guidance. Tumor specimens were processed for histological
analyses. Conventional laparoscopy revealed 24 tumors
(ranging in size from 1.6 to 13.5mm) and 28 tumors were
detected only by fluorescence laparoscopy (0.5–11mm).
The results indicate that intraoperative HY-PDD is more
sensitive than conventional laparoscopy and can clearly
distinguish rhabdomyosarcoma from healthy tissue (Urla
et al., 2015). Moreover, the authors inform about clinical
trial that will be initiated in children with advanced-stage
rhabdomyosarcoma.
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HYPERICIN IN DARK CONDITIONS OR
THE EFFECTS OF HYPERICIN WITHOUT
LIGHT-ACTIVATION
Although hypericin has been extensively studied mainly because
of its photodynamic and photocytotoxic properties, it also
possesses various positive and negative biological activities
without light-activation.
As some in vitro studies revealed cytotoxic or growth-
inhibitory effects of non-activated hypericin (Blank et al., 2001,
2003; Berlanda et al., 2010; Besic Gyenge et al., 2012) and
antiproliferative (Blank et al., 2001) and antimetastatic (Blank
et al., 2004) activities in vivo and antiangiogenic actions in vitro
(Martínez-Poveda et al., 2005) have been described, hypericin
might also show antitumor potential in the absence of light.
Moreover, one clinical study has demonstrated antiglioma
activity of hypericin in dark conditions (Couldwell et al., 2011).
However, the potential use of this natural compound in medicine
might be broader. Regarding its avidity to necrotic tissues, the
radiolabeled hypericin derivative ([123I]iodohypericin) can be
used for radio-imaging of numerous necrosis-related pathologies
(acute myocardial infarction, liver infarction) (Ni et al., 2006;
Fonge et al., 2008), including solid tumors (Van de Putte et al.,
2012).
On the other hand, hypericin can be associated with a
decrease in the chemosensitivity of cancer cells because of
its ability to induce the expression of some ATP-binding
cassette (ABC) transporters, which are well-known multidrug
resistance (MDR) components (Jendželovský et al., 2009;
Jendželovská et al., 2014; Kuchárová et al., 2015). In addition,
the hypericin-mediated attenuation of the cytotoxicity of some
chemotherapeutic agents was demonstrated (Jendželovská et al.,
2014).
Non-Activated Hypericin and Its Potential
Antitumor Activity
Hypericin-mediated photocytotoxic effects have always been
a relevant and attractive issue for researchers in the field of
oncology; however, the abilities of hypericin in the absence of
light-activation have not been studied as intensively. Although
several studies indicate that hypericin might possess some
anticancer activities even in dark conditions (Table 5).
It has been found that non-activated hypericin possesses no
cytotoxicity toward various cancer cell lines at concentrations
sufficient for its photocytotoxic action (Thomas and Pardini,
1992; Hadjur et al., 1996; Vandenbogaerde et al., 1997). However,
some in vitro studies have shown that hypericin can act as a
cytotoxic or antiproliferative agent even in the dark (Blank et al.,
2001, 2003; Berlanda et al., 2010; Besic Gyenge et al., 2012). The
presence or absence of these effects often strongly depends on
the hypericin concentration (higher concentrations are required
than for HY-PDT-mediated toxicity), treatment conditions, the
applied experimental methods, as well as on the type, origin and
sensitivity of cancer cells. Moreover, most in vitro studies have
tested the cytotoxicity of non-activated hypericin following its
single dose or during relatively short time intervals; however, the
situation after multiple fractionated hypericin dosages or during
a long-term investigation might be completely different.
Firstly, Blank et al. (2001) demonstrated the cytotoxic and
antiproliferative effect of non-activated hypericin both in vitro
and in vivo. Hypericin significantly decreased the viability
of highly metastatic murine breast adenocarcinoma (DA3HI)
and SCC (SQ2) cells. Moreover, the anticancer potential of
hypericin was observed even in vivo in DA3HI- and SQ2-derived
tumors. Even though hypericin slightly accelerated death in mice
with DA3HI-derived tumor development that was very rapid,
intraperitoneal hypericin administration (6 declining doses) in
other animals led to the inhibition of tumor growth, which
was accompanied by prolonged survival time. Moreover, the
hypericin-mediated improvement of survival was also evident
in mice with high-grade SCC tumors (Blank et al., 2001).
Subsequently, Blank et al. (2004) examined the antimetastatic
potential of non-activated hypericin and evaluated its influence
on long-term survival (up to 300 days). Again, mice with breast
adenocarcinoma or SCC tumors, which develop metastases
predominantly in the lungs, were used as experimental models.
To evaluate the impact of hypericin only on metastases, primary
tumors were surgically excised at a stage when micrometastases
already existed. Hypericin was administered intraperitoneally in
multiple declining dosages (up to 6 doses of hypericin at 5-
day intervals). In both cases of tumor origin, hypericin therapy
together with the resection of primary tumors resulted in a
significant increase in long-term animal survival compared to
the untreated control or to those animals that received surgery
alone. Moreover, the complete destruction of several, but not
all lung metastases, was evident 72 h after hypericin treatment.
The results indicate that a single hypericin dose was insufficient
to prolong the survival of animals, but fractionated hypericin
doses could prevent animal death when administered shortly
after the resection of the primary tumor (Blank et al., 2004).
Similarly, multiple hypericin doses were applied in a previous
study to obtain positive anticancer therapeutic results (Blank
et al., 2001).
Considering the potential of hypericin to destroy metastases
(Blank et al., 2004), the results are consistent with previous in
vitro findings, where a decrease in the viability of DA-3HI and
SQ2 cells was also evident 72 h after treatment (Blank et al., 2001).
However, no hypericin-mediated induction of apoptosis in the
dark was observed. The inhibition of DNA synthesis indicated
that the anticancer action of non-activated hypericin in these
cell lines was more cytostatic than cytotoxic (Blank et al., 2001).
Nevertheless, another in vitro experiment conducted by the same
research group established mitotic cell death as the mechanism
of hypericin-mediated cytotoxicity. Hypericin was responsible
for the enhanced ubiquitinylation of the Hsp90 chaperone,
resulting in the destabilization of its client proteins engaged in
the regulation of cell proliferation, including p53, Cdk4, Plk,
and Raf-1. Ultimately, cytostasis and a decrease in cell viability
with no apoptosis were observed. Mitotic cell death is generally
characterized by cell-cycle arrest in the G2/M phase, increased
cell volume and multinucleation. All these phenotypes were
evident in DA3 and SQ2 cells and even in B16.F10 melanoma
cells after hypericin treatment (Blank et al., 2003). Thus, mitotic
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TABLE 5 | Anticancer effects of hypericin in dark conditions.
Experimental model Hypericin doses and administration Effects of non-activated hypericin References
IN VITRO STUDIES
Murine breast adenocarcinoma
cell line (DA3)
Murine anaplastic SCC cell line
(SQ2)
0.065–10µM (24 h), 0.2–20µM (72 h),
0.6 and 6µM
Mild decrease in cell viability detected by MTT
assay (24 h, SQ2 cells), Significant decrease in
cell viability detected by Hemacolor assay
(72 h), Decrease in DNA synthesis detected by
3H-thymidine incorporation (72 h)
Blank et al., 2001
Murine melanoma cell line
(B16.F10) 1–40µM Cytostasis detected by BrdU incorporation
assay (72 h; doses ≤ 10µM), Reduced cell
viability detected by Hemacolor assay (72 h;
doses > 10µM); G2/M cell cycle arrest,
formation of enlarged polynucleated cells and
no evidence of apoptosis indicating mitotic cell
death; enhanced ubiquitinylation of Hsp90
resulting in increased destabilization of its client
proteins (p53, Cdk4, Plk, Raf-1)
Blank et al., 2003
Bovine aorta endothelial cells
(BAE)
Range of concentrations, 5, 10 or 20µM Inhibition of some key steps of angiogenesis
(decrease in urokinase extracellular level;
inhibition of: endothelial cells proliferation,
endothelial tube formation, migration and
invasive capability of endothelial cells)
Martínez-Poveda
et al., 2005
Human epidermoid carcinoma
cell line (A431)
Range of concentrations (up to 100µM) Antiproliferative and/or cytotoxic effect
detected by MTT assay (concentrations higher
than 3.13µM)
Berlanda et al., 2010
Human head and neck SCC
carcinoma cell lines (UMB-SCC
745, UMB-SCC 969)
0.6–10µg/ml Antiproliferative effect detected by BrdU cell
proliferation assay (all applied concentrations),
no influence on RNA integrity, initial DNA
damage (recovered after 3 h)
Besic Gyenge et al.,
2012
IN VIVO STUDIES
Balb/c mice/Murine breast
carcinoma (DA3)
Murine SCC (SQ2)
200, 100 and 50µM; intraperitoneal
injection
Reduced volume of DA3-derived tumors (66%
at 20 days after beginning of treatment),
prolonged survival time (both DA3 and SQ2
models)
Blank et al., 2001
5, 2.5, and 1.25mg/kg, 10mg/kg;
intraperitoneal injection
Increase in long-term (300 days) animal survival
(together with surgery), complete destruction of
several DA3-derived metastatic foci in lungs
(10mg/kg, 72 h)
Blank et al., 2004
CLINICAL STUDIES
Glioblastoma (35 patients)
Anaplastic astrocytoma
(7 patients)
0.05–0.50mg/kg; oral administration Stabilization or slight reduction of tumor volume
(7 of 42 patients = 17%), partial clinical
response (> 50% tumor reduction; 2 of 42
patients = 2%), mild adverse effects
(photosensitivity, erythema, vomiting, diarrhea,
etc.)
Couldwell et al., 2011
BrdU, 5-bromo-2′-deoxyuridine; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; SCC, squamous cell carcinoma.
cell death might participate in the tumoricidal and antimetastatic
functions of hypericin in the absence of light.
Martínez-Poveda et al. (2005) described another mechanism
that might be implicated in the anticancer effects of hypericin
in the dark. The results of several in vitro assays indicated that
hypericin can inhibit several key steps of angiogenesis, including
the proliferation, migration and invasion of endothelial cells,
extracellular matrix-degrading urokinase or tubular formation
onMatrigel (Martínez-Poveda et al., 2005). All these effects might
be beneficial in the prevention of tumor neovascularization.
To our knowledge, one clinical trial has investigated the
impact of hypericin on recurrent malignant gliomas (anaplastic
astrocytoma and glioblastoma) and has monitored the tolerance
of the patients to this treatment. Hypericin was administered
orally at gradually increasing dosages ranging from 0.05 to
0.5mg/kg (once each morning for up to 3 months) and was
well-tolerated (mean maximum tolerated daily dose of 0.40 ±
0.098mg/kg), although some mild skin or gastrointestinal side
effects were observed. More importantly, hypericin stabilized or
slightly reduced tumor volume (in seven out of 42 patients). In
addition, a partial response (>50% reduction of tumor volume)
was observed in two patients (Couldwell et al., 2011). These
results indicate that synthetic orally administered hypericin
can be moderately effective as an adjuvant therapy in cases
of malignant glioma; however, further clinical studies are
required.
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Hypericin as a Necrosis-Avid Agent in
Oncology
In addition to its preferential accumulation in tumors compared
to in normal healthy tissue, hypericin also has a specific strong
affinity toward necrotic tissue (Van de Putte et al., 2008a,b,c).
The mechanisms of this phenomenon have not yet been fully
elucidated; although some hypotheses already exist that consider
the binding of hypericin to specific constituents in the necrotic
space. Several radiolabeled hypericin derivatives, particularly
[123I]iodohypericin (Fonge et al., 2007) and [131I]iodohypericin
(Li et al., 2011), possess similar necrosis avidity; thus, hypericin
can be used as a potent necrosis-avid contrast agent (NACA)
for the non-invasive detection and imaging of various necrosis-
related pathologies and diseases or to assess tissue viability
and therapeutic responses. Moreover, iodohypericins as NACAs
might also be effective in relatively new approaches that combine
both tumor diagnosis and therapy, so-called “theranostic”
modalities (Table 6).
In a few initial in vivo studies, hypericin was investigated
as a potential indicator of therapeutic responses, following
various necrosis-inducing anticancer treatments. Mice bearing
intrahepatic fibrosarcoma tumors were used as an experimental
model and hypericin was injected intravenously 1 h before,
or 24 h after intratumoral ethanol injection (Van de Putte
et al., 2008b) or radiofrequency ablation (Van de Putte et al.,
2008c), which both induced tumor necrosis. Fluoromacroscopic
and fluoromicroscopic examinations confirmed that hypericin
accumulated preferentially in necrotic tissue. In the cases of
necrosis, mean fluorescence densities were about 4.5- and 5-
fold higher than in viable tumor tissue and 14- and 12-fold
higher than in normal liver tissue. These results demonstrate
the ability of hypericin to enhance the imaging contrast between
necrotic and viable tissues and ultimately, its potential role
in the early assessment of the therapeutic response (Van
de Putte et al., 2008b,c). At about the same time, tumor
uptake of radiolabeled hypericin (mono-[123I]iodohypericin)
and protohypericin (mono-[123I]iodoprotohypericin) derivatives
were tested and compared, because of the applicability of
tomographic imaging techniques instead of fluorescence-based
techniques. Radioactivity was measured using a gamma counter.
Both radiolabeled compounds were retained by the tumors,
but mono-[123I]iodohypericin appeared to be a more suitable
tumor diagnostic agent, due to its faster clearance from healthy
organs (Fonge et al., 2007). Another radiolabeled derivate,
64Cu-bis-DOTA-hypericin, was also applicable in the early
determination of the therapeutic response as its accumulation
was significantly lower in non-treated tumors than in those
treated by photothermal ablation therapy, inducing necrosis
(Song et al., 2011).
As necrotic tissue represents 30–80% of the solid tumor
mass and is rarely present in normal healthy tissue and organs,
it is a suitable target not only for cancer diagnosis, but also
for anticancer therapy. The strong avidity of iodohypericins
for necrotic tissue makes these compounds very potent in the
imaging of tumor necrosis. Furthermore, as hypericin can persist
in necrotic tumor areas much longer (up to 72 h) than in
viable tumor tissue (up to 24 h) (Van de Putte et al., 2012),
its radiolabeled derivatives could be also used for so-called
tumor necrosis therapy (TNT). This therapy is based on the
destruction of adjacent viable tumor cells by the deposition
and accumulation of radiation energy. In other words, attached
radioactive iodine “bombards” the neighboring living tumor cells
with radiation. Each successive treatment kills more tumor cells,
thus, increasing the necrotic region, which allows higher efficacy
with each treatment. As three injections of [131I]iodohypericin
reduced the volume of RIF-1-derived tumors, this radiolabeled
derivate might have potential in TNT (Van de Putte et al., 2012).
In addition, similar results, especially the intense retention of
[131I]iodohypericin in necrotic tumor tissue (over 168 h) and
inhibited tumor growth after a single dose, were obtained by Liu
et al. (2015) in mice bearing hepatomas or sarcomas.
Moreover, the approach of a necrosis-based anticancer
treatment has been expanded into a dual-targeting theranostic
strategy by administering the vascular-disrupting agent prior
to the hypericin iododerivate. Firstly, a vascular-disrupting
agent, such as combretastatin A4 phosphate (CA4P), targets
the tumor microenvironment and subsequently, iodine
radioactivity kills residual cancer cells. Several preclinical
studies have demonstrated that dual-targeting using CA4P
with [131I]iodohypericin was much more effective than single
treatments. A reduced tumor volume, a prolonged tumor
doubling time, an increase in radiation-induced cell death and
intratumoral necrosis or prolonged survival time were reported
in rats bearing liver rhabdomyosarcomas (Li et al., 2011, 2012),
in mice bearing fibrosarcomas (Li et al., 2013) and in rabbits with
liver and muscular VX2 tumors (Shao et al., 2015). Thus, the
dual-targeting theranostic approach appears to be well tolerated
and can enhance the therapeutic response, encouraging further
development for other preclinical and even clinical applications.
Non-Activated Hypericin and Its Potential
Negative Impact on Cancer Treatment
All the above-mentioned preclinical and clinical results suggest
that hypericin offers great potential in tumor diagnosis as well
as in anticancer therapy. However, this secondary metabolite
might also cause some other effects that would not be beneficial
for therapeutic outcomes. It is well-known that the efficacy of
commonly used anticancer treatment modalities is often limited
by intrinsic or acquired MDR—a multifactorial phenomenon of
the increased tolerance of cancer cells to various tumoricidal
agents. A number of cellular mechanisms can contribute to
MDR (reviewed in Stavrovskaya, 2000; Zahreddine and Borden,
2013), including the increased elimination of anticancer drugs
by tumor cells, which is mostly linked to the elevated expression
and/or activity of several ABC transporters. It has been shown
that non-activated hypericin can modulate some of these
eﬄux pumps. In vitro experiments conducted by our research
group (Jendželovský et al., 2009; Jendželovská et al., 2014;
Kuchárová et al., 2015) have revealed an increased expression
of multidrug resistance-associated protein 1 (MRP1) and breast
cancer resistance protein (BCRP) in colorectal HT-29 cells or in
ovarian A2780 and A2780cis cells following hypericin treatment
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TABLE 6 | Preclinical in vivo studies to test hypericin as a necrosis-avid agent.
Experimental model/Type
of tumor (cell line)
Hypericin derivate Detection method Effects References
C3H mice/Fibrosarcoma
(RIF-1)
[123 I]MIH Gamma counter Retention by the tumors and rapid
clearance from healthy organs (faster
clearance than [123 I]MIprotoH)
Fonge et al.,
2007
C3H/Km mice/Fibrosarcoma
(RIF-1)
hypericin FM imaging Accumulation in intratumoral necrosis (4 h
after administration)
Van de Putte
et al., 2008a
UV365 and Tungsten light, FM
imaging
Preferential accumulation in intratumoral
necrosis (intratumoral necrosis > viable
tumor > normal liver tissue), enhanced
contrast between necrotic and viable tissue
= early assessment of therapeutic
response (diagnosis)
Van de Putte
et al., 2008b,c
Nude mice/Mammary cancer
(BT474)
64CuBDH PET, autoradiography Higher accumulation in treated than in
non-treated tumors = assessment of
therapeutic response (diagnosis)
Song et al., 2011
Balb/c mice/Fibrosarcoma
(RIF-1)
hypericin, [123 I]MIH,
[131 I]MIH
FM, PET, autoradiography,
scintigraphy
Longer persistence of tracers in necrotic
than in viable tumor, stabilization of tumor
growth and reduced tumor volume (3
injections of [131 I]MIH) = potential in TNT
Van de Putte
et al., 2012
WAG/Rij
rats/Rhabdomyosarcoma (R1)
[131 I]MIH MRI, CT scan, scintigraphy, Gamma
counter, autoradiography
Reduced tumor volume, prolonged tumor
doubling time and inhibited tumor regrowth
(dual-targeting with CA4P)
Li et al., 2011
[123 I]MIH, [131 I]MIH Accumulation in intratumoral necrosis
([123 I]MIH); reduced tumor volume,
prolonged tumor doubling time and
increased intratumoral necrosis =
tumoricidal effect (dual-targeting - [131 I]MIH
with CA4P)
Li et al., 2012
SCID mice/Fibrosarcoma
(RIF-1)
[131 I]MIH MRI, scintiscan, autoradiography Accumulation in intratumoral necrosis (over
120 h); prolonged survival time, marked
radiation-induced cell death, reduced
tumor volume, prolonged tumor doubling
time (dual-targeting with CA4P)
Li et al., 2013
New Zealand white
rabbits/VX2 tumors
[131 I]MIH MRI, SPECT, autoradiography High targetability to tumor necrosis;
reduced tumor growth and prolonged
tumor doubling time (dual-targeting with
CA4P)
Shao et al., 2015
Kunming (KM)
mice/Hepatoma (H22)
Sarcoma (S180)
[131 I]MIH FM, SPECT, autoradiography Prolonged retention by the tumors, limited
systemic toxicity, tumor growth delay =
therapeutic efficacy
Liu et al., 2015
[123 I]MIH, mono-[123 I]iodohypericin; [123 I]MIprotoH, mono-[123 I]iodoprotohypericin; [131 I]MIH, mono-[131 I]iodohypericin; 64CuBDH, 64Cu-bis-DOTA-hypericin; CA4P, combretastatin A4
phosphate; CT, computed tomography; FM, fluorescencemicroscopy; MRI, magnetic resonance imaging; PET, positron emission tomography; SPECT, single-photon emission computed
tomography; TNT, tumor necrosis therapy.
in the dark. In A2780 and A2780cis cells, 0.5µM hypericin
elevated MRP1 protein levels already 6 h after the treatment
(Jendželovská et al., 2014). For HT-29 cells, an even lower
hypericin concentration (0.1 µM) was sufficient to increase
MRP1 and BCRP expression (16 h after hypericin addition)
(Jendželovský et al., 2009; Kuchárová et al., 2015). Therefore,
because many chemotherapeutic agents and photosensitizers
are substrates of the above-mentioned transporters (reviewed
in Nies et al., 2007; Robey et al., 2007), the hypericin-
mediated stimulation of eﬄux systems might lead to a decrease
in the efficacy of these therapeutic approaches when they
are applied at the same time or shortly following hypericin
treatment.
Wada et al. (2002) evaluated the impact of hypericin on the
action of several anticancer drugs, using the cervical HeLa cell
line and its resistant subline Hvr100-6 that overexpress another
MDR-related ABC transporter, P-glycoprotein (P-gp), but no
effect was observed. Several studies suggest that hypericin can
neither modulate P-gp expression nor its activity (Wada et al.,
2002; Tian et al., 2005; Jendželovský et al., 2009), which explains
its poor ability to influence the cytotoxicity and transport of
P-gp substrates, such as paclitaxel, daunorubicin, doxorubicin
or vinblastin (Wada et al., 2002). On the other hand, 24
h pre-treatment with hypericin resulted in the attenuation
of mitoxantrone cytotoxicity in HL-60 cells and cisplatin
cytotoxicity in sensitive A2780 and resistant A2780cis cells
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(Jendželovská et al., 2014). However, this effect was probably
not caused by modulation of the analyzed ABC transporters.
However, the results suggest that hypericin in the dark might
have a negative impact on the onset or progress of cell death
induced by some anticancer agents, possibly by affecting some
other mechanisms. Further studies are required, to elucidate
the specific mechanisms responsible for the above-mentioned
changes and in vivo studies will be necessary to verify the impact
of non-activated hypericin on the outcome of chemotherapy.
Moreover, some MDR mechanisms, including ABC
transporters, are also involved in drug pharmacokinetics.
The modulation of these mechanisms can affect the absorption,
distribution or clearance and ultimately, the action of the
administered xenobiotics, resulting in negative drug interactions.
Several clinical trials have demonstrated the interactions
between some chemotherapeutic agents and St. John’s wort
extract, which is often taken by oncological patients as an
antidepressant. In the first study, the enhanced metabolism
of irinotecan and consequently, decreased plasma levels of its
active metabolite (SN-38) were evaluated in cancer patients
following St. John’s wort treatment (Mathijssen et al., 2002).
Furthermore, Frye et al. (2004) and Smith et al. (2004) examined
the effect of St. John’s wort extract on the pharmacokinetics
of imatinib mesylate in healthy adult volunteers. In both
studies, imatinib was administered before and after the
treatment with St. John’s wort (300mg three times daily
for 2 weeks) and its clearance and half-life was significantly
increased or decreased, respectively, by the herb extract. Similar
results were obtained by Goey et al. (2014) using a similar
experimental design. Besides the enhanced clearance and
decreased plasma concentrations of docetaxel in cancer patients,
St. John’s wort lowered the incidence of docetaxel-mediated
toxicities. Thus, due to the risk of potential undertreatment,
combining anticancer therapeutic approaches with St. John’s
wort extracts should not be recommended to oncological
patients.
The probable reason for these effects is the induction of the
metabolic enzyme (CYP3A4) and/or the P-gp transporter by
hyperforin (Komoroski et al., 2004; Tian et al., 2005), another
St. John’s wort metabolite. However, considering the potential of
hypericin to induce the expression of some ABC eﬄux pumps,
this secondary metabolite might also contribute to negative drug
interactions with St. John’s wort. Therefore, a much broader
spectrum of antineoplastic drugs might exist, including various
chemotherapeutic agents or photosensitizers, whose actionmight
be altered due to the presence of hypericin.
SUMMARY
In this review, we have summarized the medicinal applications
of light-activated and non-activated hypericin in the field of
oncology. We have preferentially highlighted the “primary
beneficial side” of this secondary metabolite concerning its
anticancer potential, but have also outlined its “second non-
beneficial side,” which was revealed by preliminary in vitro
studies.
The vast majority of the results summarized here suggest
that hypericin in light and dark conditions might be a very
potent agent in cancer treatment and diagnosis. Besides the
well-known and intensively investigated HY-PDT and HY-PDD,
some new and promising approaches using hypericin as NACA
are becoming the focus of various research groups. Moreover,
some tested modalities, including dual-targeting, might even
improve the clinical outcome of cancer treatments. However,
in the dark, hypericin might be responsible for the limited
efficacy of conventionally applied chemotherapy or even PDT,
due to its ability to induce the expression of some ABC
transporters. Moreover, there is a suspicion that non-activated
hypericin possesses much broader biological activity. Thus, the
chronic usage of St. John’s wort extracts as an antidepressant by
oncological patients undergoing anticancer treatment should be
avoided.
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